International journal of heart failure最新文献_第2页

Differences in the Effects of Beta-Blockers Depending on Heart Rate at Discharge in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. 射血分数保留型心力衰竭和心房颤动患者出院时心率不同，β-受体阻滞剂的效果也不同。

International journal of heart failure Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.36628/ijhf.2023.0052

Young In Kim, Min-Soo Ahn, Byung-Su Yoo, Jang-Young Kim, Jung-Woo Son, Young Jun Park, Sung Hwa Kim, Dae Ryong Kang, Hae-Young Lee, Seok-Min Kang, Myeong-Chan Cho

{"title":"Differences in the Effects of Beta-Blockers Depending on Heart Rate at Discharge in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation.","authors":"Young In Kim, Min-Soo Ahn, Byung-Su Yoo, Jang-Young Kim, Jung-Woo Son, Young Jun Park, Sung Hwa Kim, Dae Ryong Kang, Hae-Young Lee, Seok-Min Kang, Myeong-Chan Cho","doi":"10.36628/ijhf.2023.0052","DOIUrl":"10.36628/ijhf.2023.0052","url":null,"abstract":"Background and objectives: Beta-blockers (BBs) improve prognosis in heart failure (HF), which is mediated by lowering heart rate (HR). However, HR has no prognostic implication in atrial fibrillation (AF) and also BBs have not been shown to improve prognosis in heart failure with preserved ejection fraction (HFpEF) with AF. This study assessed the prognostic implication of BB in HFpEF with AF according to discharge HR.Methods: From the Korean Acute Heart Failure Registry, 687 patients with HFpEF and AF were selected. Study subjects were divided into 4 groups based on 75 beats per minute (bpm) of HR at discharge and whether or not they were treated with BB at discharge.Results: Of the 687 patients with HFpEF and AF, 128 (36.1%) were in low HR group and 121 (36.4%) were in high HR group among those treated with BB at discharge. In high HR group, HR at discharge was significantly faster in BB non-users (85.5±9.1 bpm vs. 89.2±12.5 bpm, p=0.005). In the Cox model, BB did not improve 60-day rehospitalization (hazard ratio, 0.93; 95% confidence interval [95% CI], 0.35-2.47) or mortality (hazard ratio, 0.77; 95% CI, 0.22-2.74) in low HR group. However, in high HR group, BB treatment at discharge was associated with 82% reduced 60-day HF rehospitalization (hazard ratio, 0.18; 95% CI, 0.04-0.81), but not with mortality (hazard ratio, 0.77; 95% CI, 0.20-2.98).Conclusions: In HFpEF with AF, in patients with HR over 75 bpm at discharge, BB treatment at discharge was associated with a reduced 60-day rehospitalization rate.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":"6 3","pages":"119-126"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Causes of Hospitalization in Patients With Cardiorenal Syndrome Across the Spectrum of Ejection Fraction. 不同射血分数的心肾综合征患者住院原因。

International journal of heart failure Pub Date : 2024-06-25 eCollection Date: 2024-07-01 DOI: 10.36628/ijhf.2023.0065

Yosef Manla, Obada Kholoki, Nizar Attallah, Feras Bader

引用次数: 0

Heart Failure With Preserved Ejection Fraction and Frailty: From Young to Superaged Coexisting HFpEF and Frailty. 射血分数保留型心力衰竭与虚弱：从年轻到超高龄并存的 HFpEF 和虚弱。

International journal of heart failure Pub Date : 2024-06-21 eCollection Date: 2024-07-01 DOI: 10.36628/ijhf.2023.0064

Amina Rakisheva, Anzhela Soloveva, Anastasia Shchendrygina, Ilya Giverts

{"title":"Heart Failure With Preserved Ejection Fraction and Frailty: From Young to Superaged Coexisting HFpEF and Frailty.","authors":"Amina Rakisheva, Anzhela Soloveva, Anastasia Shchendrygina, Ilya Giverts","doi":"10.36628/ijhf.2023.0064","DOIUrl":"10.36628/ijhf.2023.0064","url":null,"abstract":"Being commonly diagnosed in elderly women and associated with comorbidities as well as ageing-related cardio-vascular changes, heart failure with preserved ejection fraction (HFpEF) has been recently considered as a distinct cardiogeriatric syndrome. Frailty is another frequent geriatric syndrome. HFpEF and frailty share common underlying mechanisms, often co-exist, and represent each other's risk factors. A threshold of 65 years old is usually used to screen patients for both frailty and HFpEF in research and clinical settings. However, both HFpEF and frailty are very heterogenous conditions that may develop at younger ages. In this review we aim to provide a broader overview on the coexistence of HFpEF and frailty throughout the lifetime. We hypothesize that HFpEF and frailty patients' profiles (young, elderly, superaged) represent a continuum of the common ageing process modified by cumulative exposure to risk factors resulting to a presentation of HFpEF and frailty at different ages. We believe, that suggested approach might stimulate assessment of frailty in HFpEF assessment and vice versa regardless of age and early implementation of targeted interventions. Future studies of pathophysiology, clinical features, and outcomes of frailty in HFpEF by age are needed.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":"6 3","pages":"93-106"},"PeriodicalIF":0.0,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Another, A Few Good Device for End Stage Heart Failure. 另一种，治疗终末期心力衰竭的几种好设备。

International journal of heart failure Pub Date : 2024-04-23 eCollection Date: 2024-04-01 DOI: 10.36628/ijhf.2024.0023

Jooyeon Lee, Jaewon Oh, Seok-Min Kang

引用次数: 0

Heart Failure Statistics 2024 Update: A Report From the Korean Society of Heart Failure. 2024 年心力衰竭统计更新：韩国心力衰竭协会报告》。

International journal of heart failure Pub Date : 2024-04-18 eCollection Date: 2024-04-01 DOI: 10.36628/ijhf.2024.0010

Chan Joo Lee, Hokyou Lee, Minjae Yoon, Kyeong-Hyeon Chun, Min Gyu Kong, Mi-Hyang Jung, In-Cheol Kim, Jae Yeong Cho, Jeehoon Kang, Jin Joo Park, Hyeon Chang Kim, Dong-Ju Choi, Jungkuk Lee, Seok-Min Kang

{"title":"Heart Failure Statistics 2024 Update: A Report From the Korean Society of Heart Failure.","authors":"Chan Joo Lee, Hokyou Lee, Minjae Yoon, Kyeong-Hyeon Chun, Min Gyu Kong, Mi-Hyang Jung, In-Cheol Kim, Jae Yeong Cho, Jeehoon Kang, Jin Joo Park, Hyeon Chang Kim, Dong-Ju Choi, Jungkuk Lee, Seok-Min Kang","doi":"10.36628/ijhf.2024.0010","DOIUrl":"https://doi.org/10.36628/ijhf.2024.0010","url":null,"abstract":"Background and objectives: The number of people with heart failure (HF) is increasing worldwide, and the social burden is increasing as HF has high mortality and morbidity. We aimed to provide updated trends on the epidemiology of HF in Korea to shape future social measures against HF.Methods: We used the National Health Information Database of the National Health Insurance Service to determine the prevalence, incidence, hospitalization rate, mortality rate, comorbidities, in-hospital mortality, and healthcare cost of patients with HF from 2002 to 2020 in Korea.Results: The prevalence of HF in the total Korean population rose from 0.77% in 2002 to 2.58% (1,326,886 people) in 2020. Although the age-standardized incidence of HF decreased over the past 18 years, the age-standardized prevalence increased. In 2020, the hospitalization rate for any cause in patients with HF was 1,166 per 100,000 persons, with a steady increase from 2002. In 2002, the HF mortality was 3.0 per 100,000 persons, which rose to 15.6 per 100,000 persons in 2020. While hospitalization rates and in-hospital mortality for patients with HF increased, the mortality rate for patients with HF did not (5.8% in 2020), and the one-year survival rate from the first diagnosis of HF improved. The total healthcare costs for patients with HF were approximately $2.4 billion in 2020, a 16-fold increase over the $0.15 billion in 2002.Conclusions: The study's results underscore the growing socioeconomic burden of HF in Korea, driven by an aging population and increasing HF prevalence.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":"6 2","pages":"56-69"},"PeriodicalIF":0.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11058436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Role of Vitamin D Deficiency Correction in Heart Failure Management: Insights and Prospects. 探索维生素 D 缺乏症纠正在心力衰竭治疗中的作用：洞察与展望

International journal of heart failure Pub Date : 2024-04-17 eCollection Date: 2024-04-01 DOI: 10.36628/ijhf.2024.0019

Hyung Yoon Kim

引用次数: 0

The Dual Burden of Frailty and Heart Failure. 衰弱和心力衰竭的双重负担。

International journal of heart failure Pub Date : 2024-04-15 eCollection Date: 2024-07-01 DOI: 10.36628/ijhf.2023.0057

Cristiana Vitale, Ilaria Spoletini, Giuseppe M C Rosano

引用次数: 0

The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper. 第三次全国性韩国心衰 III 登记（KorHF III）：研究设计文件。

International journal of heart failure Pub Date : 2024-04-01 DOI: 10.36628/ijhf.2024.0001

Minjae Yoon, Eung Ju Kim, Seong Woo Han, Seong-Mi Park, In-Cheol Kim, Myeong-Chan Cho, Hyo-Suk Ahn, Mi-Seung Shin, Seok Jae Hwang, Jin-Ok Jeong, Dong Heon Yang, Jae-Joong Kim, Jin Oh Choi, Hyun-Jai Cho, Byung-Su Yoo, Seok-Min Kang, Dong-Ju Choi

{"title":"The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper.","authors":"Minjae Yoon, Eung Ju Kim, Seong Woo Han, Seong-Mi Park, In-Cheol Kim, Myeong-Chan Cho, Hyo-Suk Ahn, Mi-Seung Shin, Seok Jae Hwang, Jin-Ok Jeong, Dong Heon Yang, Jae-Joong Kim, Jin Oh Choi, Hyun-Jai Cho, Byung-Su Yoo, Seok-Min Kang, Dong-Ju Choi","doi":"10.36628/ijhf.2024.0001","DOIUrl":"https://doi.org/10.36628/ijhf.2024.0001","url":null,"abstract":"With advancements in both pharmacologic and non-pharmacologic treatments, significant changes have occurred in heart failure (HF) management. The previous Korean HF registries, namely the Korea Heart Failure Registry (KorHF-registry) and Korean Acute Heart Failure Registry (KorAHF-registry), no longer accurately reflect contemporary acute heart failure (AHF) patients. Our objective is to assess contemporary AHF patients through a nationwide registry encompassing various aspects, such as clinical characteristics, management approaches, hospital course, and long-term outcomes of individuals hospitalized for AHF in Korea. This prospective observational multicenter cohort study (KorHF III) is organized by the Korean Society of Heart Failure. We aim to prospectively enroll 7,000 or more patients hospitalized for AHF at 47 tertiary hospitals in Korea starting from March 2018. Eligible patients exhibit signs and symptoms of HF and demonstrate either lung congestion or objective evidence of structural or functional cardiac abnormalities in echocardiography, or isolated right-sided HF. Patients will be followed up for up to 5 years after enrollment in the registry to evaluate long-term clinical outcomes. KorHF III represents the nationwide AHF registry that will elucidate the clinical characteristics, management strategies, and outcomes of contemporary AHF patients in Korea.Trial registration: ClinicalTrials.gov Identifier: NCT04329234.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":"6 2","pages":"70-75"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11058439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF. 精准心脏病学：针对 HFmrEF 和 HFpEF 的表型靶向疗法。

International journal of heart failure Pub Date : 2024-03-25 eCollection Date: 2024-04-01 DOI: 10.36628/ijhf.2023.0058

Giuseppe M C Rosano, Cristiana Vitale, Ilaria Spoletini

引用次数: 0

Is It Time to Expand the Indication of DOAC to Patients With Cardiac Amyloidosis and Atrial Fibrillation? 是时候将 DOAC 的适应症扩展至心脏淀粉样变性和心房颤动患者了吗？

International journal of heart failure Pub Date : 2024-01-22 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2024.0002

So-Ryoung Lee, Jung-Min Choi

引用次数: 0